Enhanced eryptosis following auranofin exposure

Cellular Physiology and Biochemistry

Volumn 37, Issue 3, 2015, Pages 1018-1028

  Alzoubi, Kousi ^a   Egler, Jasmin ^a   Abed, Majed ^a   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Auranofin; Calcium; Cell volume; Eryptosis; Oxidative stress; Phosphatidylserine; ROS

Indexed keywords

AURANOFIN; CALCIUM ION; DICHLORODIHYDROFLUORESCEIN DIACETATE; HEMOGLOBIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; CALCIUM;

ARTICLE; CELL DEATH; CELL MEMBRANE; CELL SURFACE; CELL VOLUME; CYTOSOL; DRUG EXPOSURE; ERYPTOSIS; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; APOPTOSIS; CELL SIZE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM;

ANNEXIN A5; APOPTOSIS; AURANOFIN; CALCIUM; CELL MEMBRANE; CELL SIZE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HEMOLYSIS; HUMANS; OXIDATIVE STRESS; PHOSPHATIDYLSERINES;

EID: 84942292173     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430228     Document Type: Article

References (98)

1. Fricker SP: Strategies for the biological evaluation of gold anticancer agents. Anticancer Agents Med Chem 2011; 11:940-952.
2. Madeira JM, Gibson DL, Kean W.F., Klegeris A: The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 2012; 20:297-306.
3. Ramiro S, Gaujoux-Viala C, Nam J.L., Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewe R: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73:529-535.
4. van Roon E.N., van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR: An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clin Ther 2009; 31:1737-1746.
5. Yamashita M, Ohuchi K, Takayanagi M: Effects of chrisotherapeutic gold compounds on prostaglandin E2 production. Curr Drug Targets Inflamm Allergy 2003; 2:216-223.
6. Casini A, Messori L: Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr Top Med Chem 2011; 11:2647-2660.
7. Lima JC, Rodriguez L: Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action. Anticancer Agents Med Chem 2011; 11:921-928.
8. Angelucci F, Miele AE, Boumis G, Brunori M., Dimastrogiovanni D, Bellelli A: Macromolecular bases of antischistosomal therapy. Curr Top Med Chem 2011; 11:2012-2028.
9. Debnath A, Ndao M, Reed SL: Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 2013; 4:66-71.
10. Sharlow ER, Leimgruber S, Murray S., Lira A, Sciotti RJ, Hickman M, Hudson T., Leed S, Caridha D, Barrios A.M., Close D., Grogl M, Lazo JS: Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol 2014; 9:663-672.
11. Chirullo B, Sgarbanti R, Limongi D., Shytaj IL, Alvarez D, Das B, Boe A., DaFonseca S, Chomont N, Liotta L., Petricoin EI, Norelli S, Pelosi E, Garaci E., Savarino A, Palamara AT: A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis 2013; 4:e944.
12. Fonteh PN, Keter FK, Meyer D: HIV therapeutic possibilities of gold compounds. Biometals 2010; 23:185-196.
13. Chen X, Shi X, Zhao C., Li X, Lan X, Liu S., Huang H, Liu N, Liao S., Zang D, Song W, Liu Q., Carter BZ, Dou QP, Wang X, Liu J: Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and - independent mechanisms. Oncotarget 2014; 5:9118-9132.
14. Fan C, Zheng W, Fu X., Li X, Wong YS, Chen T: Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis 2014; 5:e1191.
15. Ferraz KS, Da Silva JG, Costa FM, Mendes BM, Rodrigues BL, dos Santos RG, Beraldo H: N(4)-tolyl-2-acetylpyridine thiosemicarbazones and their platinum(II,IV) and gold(III) complexes: cytotoxicity against human glioma cells and studies on the mode of action. Biometals 2013; 26:677-691.
16. Liu C, Liu Z, Li M., Li X, Wong YS, Ngai S.M., Zheng W., Zhang Y, Chen T: Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. PLoS One 2013; 8:e53945.
17. Varghese E, Busselberg D: Auranofin, an anti-rheumatic gold compound, modulates apoptosis by elevating the intracellular calcium concentration ([ca2+]I) in mcf-7 breast cancer cells. Cancers (Basel) 2014; 6:2243-2258.
18. Cohen-Kutner M., Khomsky L, Trus M., Aisner Y, Niv MY, Benhar M, Atlas D: Thioredoxin-mimetic peptides (TXM) reverse auranofin induced apoptosis and restore insulin secretion in insulinoma cells. Biochem Pharmacol 2013; 85:977-990.
19. Dai B, Yoo SY, Bartholomeusz G, Graham R.A., Majidi M., Yan S, Meng J, Ji L., Coombes K, Minna JD, Fang B, Roth JA: KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res 2013; 73:5532-5543.
20. Fiskus W, Saba N, Shen M., Ghias M, Liu J, Gupta S.D., Chauhan L., Rao R, Gunewardena S, Schorno K., Austin CP, Maddocks K, Byrd J, Melnick A., Huang P, Wiestner A, Bhalla KN: Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res 2014; 74:2520-2532.
21. Liu JJ, Liu Q, Wei H.L., Yi J., Zhao HS, Gao LP: Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells. Pharmazie 2011; 66:440-444.
22. Pessetto ZY, Weir SJ, Sethi G, Broward M.A., Godwin AK: Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 2013; 12:1299-1309.
23. Sun N, Hao JR, Li X.Y., Yin XH, Zong YY, Zhang GY, Gao C: GluR6-FasL-Trx2 mediates denitrosylation and activation of procaspase-3 in cerebral ischemia/reperfusion in rats. Cell Death Dis 2013; 4:e771.
24. You BR, Shin HR, Han B.R., Kim SH, Park WH: Auranofin induces apoptosis and necrosis in HeLa cells via oxidative stress and glutathione depletion. Mol Med Rep 2015; 11:1428-1434.
25. Zhang H, Du Y, Zhang X., Lu J, Holmgren A: Glutaredoxin 2 reduces both thioredoxin 2 and thioredoxin 1 and protects cells from apoptosis induced by auranofin and 4-hydroxynonenal. Antioxid Redox Signal 2014; 21:669-681.
26. Chen X, Zhou HJ, Huang Q, Lu L., Min W: Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis. Anticancer Agents Med Chem 2014; 14:946-954.
27. Park SH, Lee JH, Berek J.S., Hu MC: Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol 2014; 45:1691-1698.
28. Park N, Chun YJ: Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J Toxicol Environ Health A 2014; 77:1467-1476.
29. Brenol JC, Chahade W, De Freitas GG, De Padua PM, Rachid A, Samara A, Seda H., Ximenes AC: Efficacy of auranofin as demonstrated by improvement in clinical parameters and decrease in anti-inflammatory usage: a long-term, multicenter study. Scand J Rheumatol Suppl 1986; 63:37-45.
30. Brewer EJ, Jr., Giannini EH, Person DA: Early experiences with auranofin in juvenile rheumatoid arthritis. Am J Med 1983; 75:152-156.
31. Giannini EH, Brewer EJ, Jr., Person DA: Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983; 102:138-141.
32. Miyamoto S, Inoue T: [Gold compounds and D-penicillamine for therapy of rheumatoid arthritis]. Nihon Rinsho 1992; 50:515-520.
33. Lang PA, Kaiser S, Myssina S., Wieder T, Lang F, Huber SM: Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003; 285:C1553-C1560.
34. Lang E, Qadri SM, Lang F: Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol 2012; 44:1236-1243.
35. Alesutan I, Bobbala D, Qadri S.M., Estremera A., Foller M, Lang F: Beneficial effect of aurothiomalate on murine malaria. Malar J 2010; 9:118.
36. Lau IP, Chen H, Wang J., Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012; 6:847-856.
37. Sopjani M, Foller M, Lang F: Gold stimulates Ca2+ entry into and subsequent suicidal death of erythrocytes. Toxicology 2008; 244:271-279.
38. Abed M, Towhid ST, Mia S, Pakladok T., Alesutan I, Borst O, Gawaz M., Gulbins E, Lang F: Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012; 303:C991-999.
39. Maellaro E, Leoncini S, Moretti D., Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013; 50:489-495.
40. Jilani K, Qadri SM, Lang F: Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell Physiol Biochem 2013; 32:1600-1609.
41. Vota DM, Maltaneri RE, Wenker S.D., Nesse AB, Vittori DC: Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013; 65:145-157.
42. Zappulla D: Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr 2008; 3:30-34.
43. Zbidah M, Lupescu A, Jilani K., Lang F: Stimulation of suicidal erythrocyte death by fumagillin. Basic Clin Pharmacol Toxicol 2013; 112:346-351.
44. Abed M, Herrmann T, Alzoubi K., Pakladok T, Lang F: Tannic Acid induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32:1106-1116.
45. Ahmed MS, Langer H, Abed M., Voelkl J, Lang F: The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013; 37:158-167.
46. Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M., Koberle M, Lang E, Dreischer P., Biedermann T, Duszenko M, Lang F., Bosman GJ, Wieder T: Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013; 32:801-813.
47. Alzoubi K, Honisch S, Abed M., Lang F: Triggering of Suicidal Erythrocyte Death by Penta-O-galloyl-beta-d-glucose. Toxins (Basel) 2014; 6:54-65.
48. Jilani K, Lang F: Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane. Toxins (Basel) 2013; 5:703-716.
49. Jilani K, Enkel S, Bissinger R., Almilaji A, Abed M, Lang F: Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013; 5:1230-1243.
50. Lupescu A, Bissinger R, Jilani K., Lang F: Triggering of suicidal erythrocyte death by celecoxib. Toxins (Basel) 2013; 5:1543-1554.
51. Lupescu A, Jilani K, Zbidah M., Lang F: Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32:291-299.
52. Abed M, Zoubi KA, Theurer M, Lang F: Effect of dermaseptin on erythrocytes. Basic Clin Pharmacol Toxicol 2013; 113:347-352.
53. Arnold M, Lang E, Modicano P., Bissinger R, Faggio C, Abed M., Lang F: Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014; 114:421-426.
54. Oswald G, Alzoubi K, Abed M., Lang F: Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014; 114:311-317.
55. Bissinger R, Malik A, Jilani K., Lang F: Triggering of Erythrocyte Cell Membrane Scrambling by Salinomycin. Basic Clin Pharmacol Toxicol 2014; 10.1111/bcpt.12250
56. Abed M, Feger M, Alzoubi K., Pakladok T, Frauenfeld L, Geiger C., Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013; 37:567-578.
57. Alzoubi K, Calabròa S, Bissinger R., Abed M, Faggio C, Lang F: Stimulation of Suicidal Erythrocyte Death by Artesunate. Cell Physiol Biochem 2014; 34:2232-2244.
58. Arnold M, Bissinger R, Lang F: Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014; 34:1756-1767.
59. Bissinger R, Fischer S, Jilani K., Lang F: Stimulation of Erythrocyte Death by Phloretin. Cell Physiol Biochem 2014; 34:2256-2265.
60. Bissinger R, Lupescu A, Zelenak C., Jilani K, Lang F: Stimulation of eryptosis by cryptotanshinone. Cell Physiol Biochem 2014; 34:432-442.
61. Bissinger R, Modicano P, Frauenfeld L., Lang E, Jacobi J, Faggio C., Lang F: Estramustine-induced suicidal erythrocyte death. Cell Physiol Biochem 2013; 32:1426-1436.
62. Jacobi J, Lang E, Bissinger R., Frauenfeld L, Modicano P, Faggio C., Abed M, Lang F: Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014; 33:1516-1526.
63. Lupescu A, Bissinger R, Herrmann T., Oswald G, Jilani K, Lang F: Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014; 33:670-680.
64. Lupescu A, Bissinger R, Warsi J., Jilani K, Lang F: Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem 2014; 33:1838-1848.
65. Malik A, Bissinger R, Calabro S., Faggio C, Jilani K, Lang F: Aristolochic Acid Induced Suicidal Erythrocyte Death. Kidney Blood Press Res 2014; 39:408-419.
66. Tesoriere L, Attanzio A, Allegra M., Cilla A, Gentile C, Livrea MA: Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014; 34:1075-1089.
67. Voelkl J, Alzoubi K, Mamar A.K., Ahmed MS, Abed M, Lang F: Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013; 38:42-51.
68. Zhang R, Xiang Y, Ran Q., Deng X, Xiao Y, Xiang L., Li Z: Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem 2014; 34:1780-1791.
69. Amer J, Goldfarb A, Fibach E: Flow cytometric measurement of reactive oxygen species production by normal and thalassaemic red blood cells. Eur J Haematol 2003; 70:84-90.
70. Koeberle SC, Romir J, Fischer S., Koeberle A, Schattel V, Albrecht W., Grutter C, Werz O, Rauh D., Stehle T, Laufer SA: Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol 2012; 8:141-143.
71. Kim IS, Jin JY, Lee I.H., Park SJ: Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 2004; 142:749-755.
72. Park SJ, Kim IS: The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 2005; 146:506-513.
73. Harrison HE, Bunting H, Ordway N.K., Albrink WS: The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947; 86:339-356.
74. Foller M, Bobbala D, Koka S., Huber SM, Gulbins E, Lang F: Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem 2009; 24:133-140.
75. Kirk K: Membrane transport in the malaria-infected erythrocyte. Physiol Rev 2001; 81:495-537.
76. Ayi K, Giribaldi G, Skorokhod A., Schwarzer E, Prendergast PT, Arese P: 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother 2002; 46:3180-3184.
77. Ayi K, Turrini F, Piga A., Arese P: Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004; 104:3364-3371.
78. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F., Ulliers D, Simula G, Luzzatto L., Arese P: Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998; 92:2527-2534.
79. Koka S, Huber SM, Boini K.M., Lang C., Foller M, Lang F: Lead decreases parasitemia and enhances survival of Plasmodium berghei-infected mice. Biochem Biophys Res Commun 2007; 363:484-489.
80. Koka S, Lang C, Niemoeller O.M., Boini KM, Nicolay JP, Huber SM, Lang F: Influence of NO synthase inhibitor L-NAME on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2008; 21:481-488.
81. Borst O, Abed M, Alesutan I., Towhid ST, Qadri SM, Foller M, Gawaz M., Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012; 302:C644-C651.
82. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999; 6:76-82.
83. Chung SM, Bae ON, Lim K.M., Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007; 27:414-421.
84. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005; 62:971-988.
85. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999; 107:300-302.
86. Gallagher PG, Chang SH, Rettig M P, Neely JE, Hillery C.A., Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003; 101:4625-4627.
87. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A., Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A., Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007; 213:699-709.
88. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996; 88:1873-1880.
89. Abed M, Artunc F, Alzoubi K., Honisch S, Baumann D, Foller M., Lang F: Suicidal erythrocyte death in endstage renal disease. J Mol Med (Berl) 2014; 92:871-879.
90. Calderon-Salinas J.V., Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011; 357:171-179.
91. Polak-Jonkisz D., Purzyc L: Ca(2+) influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012; 34:209-210; author reply 210.
92. Lang PA, Beringer O, Nicolay J.P., Amon O., Kempe DS, Hermle T, Attanasio P, Akel A., Schafer R, Friedrich B, Risler T., Baur M, Olbricht CJ, Zimmerhackl L.B., Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006; 84:378-388.
93. Nicolay J.P., Schneider J, Niemoeller O.M., Artunc F., Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006; 18:223-232.
94. Lang E, Gatidis S, Freise N.F., Bock H., Kubitz R, Lauermann C, Orth H.M., Klindt C., Schuier M, Keitel V, Reich M., Liu G, Schmidt S, Xu H.C., Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E., Lang F, Haussinger D, Lang KS, Foller M, Lang PA: Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015; 61:275-284.
95. Qadri SM, Mahmud H, Lang E., Gu S, Bobbala D, Zelenak C., Jilani K, Siegfried A, Foller M., Lang F: Enhanced suicidal erythrocyte death in mice carrying a loss-of-function mutation of the adenomatous polyposis coli gene. J Cell Mol Med 2012; 16:1085-1093.
96. Kempe DS, Akel A, Lang P.A., Hermle T., Biswas R, Muresanu J, Friedrich B., Dreischer P, Wolz C, Schumacher U., Peschel A, Gotz F, Doring G., Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007; 85:273-281.
97. Lang KS, Roll B, Myssina S., Schittenhelm M, Scheel-Walter HG, Kanz L, Fritz J., Lang F, Huber SM, Wieder T: Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2002; 12:365-372.
98. Lang PA, Schenck M, Nicolay J.P., Becker JU, Kempe DS, Lupescu A, Koka S., Eisele K, Klarl BA, Rubben H, Schmid K.W., Mann K., Hildenbrand S, Hefter H, Huber S.M., Wieder T., Erhardt A, Haussinger D, Gulbins E., Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007; 13:164-170.